Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Release Date: January 7, 2026

Expiration Date: February 11, 2026

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in the management of endocrine-sensitive HR+/HER2− metastatic breast cancer (mBC) with a focus on treatment options following first-line endocrine therapy plus a CDK4/6 inhibitor. In this educational program, these experts discuss the role of mutational testing to guide therapy selection and the efficacy and safety of next-generation targeted therapies, including oral SERDs and PI3K, AKT, and mTOR inhibitors. The program also addresses best practices for managing adverse effects and uses a case-based format to provide practical insights to improve patient care.

This educational activity is an archive of the live symposium held on December 17, 2025.

Target Audience

This educational program is primarily directed toward community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment of mBC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply guideline-concordant approaches for molecular testing in patients with HR+/HER2− mBC across the disease continuum
• Evaluate recent real-world evidence providing practical insights into the use of targeted treatment strategies for HR+/HER2− mBC
• Integrate clinical trial and real-world data alongside patient- and disease-specific characteristics into personalized treatment decisions for patients with HR+/HER2− mBC
• Develop evidence-based strategies for monitoring and mitigating adverse effects associated with targeted therapies for HR+/HER2− mBC